Neonatal Phase 1 Valacyclovir Study
Key facts
- Who runs it
- National Institute of Allergy and Infectious Diseases (NIAID)
- Where
- Atlanta, Birmingham, Charlotte, Columbus, Louisville, Milwaukee, Minneapolis, Omaha, Queens, Rochester, St Louis, and Syracuse, United StatesSee the 12 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 17 people enrolled
- Started
- 7 Aug 2023
- Ended
- 15 Jul 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Valacyclovir
- Record updated
- 23 July 2026
Who can take part
- Age
- 1 day to 2 days
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Signed informed consent from parent(s) or legal guardian(s)
- Maternal history of genital HSV infection
- Maternal receipt of oral acyclovir, valacyclovir, or famciclovir suppressive therapy for >/= 7 days prior to delivery
- Gestational age >/= 38 weeks at birth
- </= 2 days of age at study enrollment*
- Weight at study enrollment >/= 2,000 grams; For purposes of this study, the calendar day of birth is Day of Life 0
Who cannot take part
- Current receipt in the neonate of acyclovir, ganciclovir, famciclovir, or any investigational drugs
- Evidence of neonatal HSV infection
- Infants known to be born to women who are HIV positive (but HIV testing is not required for study entry)
- Evidence of sepsis
- Known renal anomalies or dysfunction
- Maternal genital lesions suspicious for HSV at the time of delivery
Where in United States
- Emory University School of MedicineAtlanta, United States
- Children's of Alabama Child Health Research Unit (CHRU)Birmingham, United States
- Atrium Health ID Consultants & Infusion Care SpecialistsCharlotte, United States
- Nationwide Children's HospitalColumbus, United States
- University of Louisville School of Medicine - Norton Children's Hospital - Infectious DiseasesLouisville, United States
- Medical College of WisconsinMilwaukee, United States
- M Health Fairview Masonic Children's HospitalMinneapolis, United States
- Children's NebraskaOmaha, United States
- Steven and Alexandra Cohen Childrens Medical Center of New York - New Hyde Park - Infectious DiseaseQueens, United States
- University of Rochester Medical Center - Strong Memorial Hospital - Infectious DiseasesRochester, United States
- Washington University in St. LouisSt Louis, United States
- SUNY Upstate Medical University Hospital - PediatricsSyracuse, United States
About the trial
What the trial wants to find out
A Phase 1 study that will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL. Neonates at risk of acquiring neonatal HSV will be enrolled in one of 2 cohorts. Cohort 1 will be comprised of eight subjects who will receive an initial dose of 10ml/kg of oral valacyclovir. Samples for PK assessments will be obtained to assess the exposure concentration. If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. The dose that these subjects will receive will be predicated upon the pharmacokinetic data from Cohort 1.
The 2 groups in the trial
- Cohort 1Treatment being tested
A cohort of neonates who are at risk of acquiring neonatal herpes simplex virus disease will receive 10 mg/kg of valacyclovir will be administered orally two times daily for 5 days. N=8
Treatment: Valacyclovir
- Cohort 2Treatment being tested
If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. If the mean of observed acyclovir exposures of subjects in Cohort 1 are below 24,000 ngxhr/mL, AND if no Grade 3 or Grade 4 AEs or SAEs are detected in any of the study subjects, then the 8 subjects enrolled in Cohort 2 will receive oral valacyclovir at a dose of 20 mg/kg administered two times daily for 5 days. Alternatively, if the mean of observed acyclovir exposures of subjects in Cohort 1 are above 48,000 ngxhr/mL AND if no Grade 3 or Grade 4 AEs or SAEs are detected in any of the study subjects, then the 8 subjects enrolled in Cohort 2 will receive oral valacyclovir at a dose that has been linearly adjusted downward to target 36,000 ngxh/mL area-under-the-concentration-time curve from 0 to 12 hours (AUC12).
Treatment: Valacyclovir
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I Adaptive, Multiple Dose Pharmacokinetic and Safety Assessment of Valacyclovir in Infants at Risk of Acquiring Neonatal Herpes Simplex Virus Disease
- Record updated
- 23 July 2026